Copyright Reports & Markets. All rights reserved.

Global Urological Cancer Therapeutics Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Urological Cancer Therapeutics Drugs Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Overview: Global Urological Cancer Therapeutics Drugs Revenue by Type: 2015 VS 2019 VS 2025
      • 1.2.2 Xofigo (radium Ra 223 dichloride)
      • 1.2.3 Jevtana (cabazitaxel)
      • 1.2.4 Inlyta (axitinib)
      • 1.2.5 Votrient (pazopanib hydrochloride)
      • 1.2.6 Sutent (sunitinib malate)
      • 1.2.7 Zytiga (abiraterone acetate)
      • 1.2.8 Xtandi (enzalutamide)
      • 1.2.9 Opdivo (nivolumab)
      • 1.2.10 Provenge (sipuleucel-T)
    • 1.3 Market Analysis by Application
      • 1.3.1 Overview: Global Urological Cancer Therapeutics Drugs Revenue by Application: 2015 VS 2019 VS 2025
      • 1.3.2 Hospital
      • 1.3.3 Medical Research Laboratory
      • 1.3.4 Others
    • 1.4 Overview of Global Urological Cancer Therapeutics Drugs Market
      • 1.4.1 Global Urological Cancer Therapeutics Drugs Market Status and Outlook (2015-2025)
      • 1.4.2 North America (United States, Canada and Mexico)
      • 1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
      • 1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      • 1.4.5 South America, Middle East & Africa
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Novartis
      • 2.1.1 Novartis Details
      • 2.1.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.1.3 Novartis SWOT Analysis
      • 2.1.4 Novartis Product and Services
      • 2.1.5 Novartis Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.2 Celgene Corporation
      • 2.2.1 Celgene Corporation Details
      • 2.2.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.2.3 Celgene Corporation SWOT Analysis
      • 2.2.4 Celgene Corporation Product and Services
      • 2.2.5 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.3 AstraZeneca
      • 2.3.1 AstraZeneca Details
      • 2.3.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.3.3 AstraZeneca SWOT Analysis
      • 2.3.4 AstraZeneca Product and Services
      • 2.3.5 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.4 Pfizer
      • 2.4.1 Pfizer Details
      • 2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.4.3 Pfizer SWOT Analysis
      • 2.4.4 Pfizer Product and Services
      • 2.4.5 Pfizer Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.5 Abbott Laboratories
      • 2.5.1 Abbott Laboratories Details
      • 2.5.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.5.3 Abbott Laboratories SWOT Analysis
      • 2.5.4 Abbott Laboratories Product and Services
      • 2.5.5 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.6 Johnson & Johnson
      • 2.6.1 Johnson & Johnson Details
      • 2.6.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.6.3 Johnson & Johnson SWOT Analysis
      • 2.6.4 Johnson & Johnson Product and Services
      • 2.6.5 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.7 Ferring Pharmaceuticals
      • 2.7.1 Ferring Pharmaceuticals Details
      • 2.7.2 Ferring Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.7.3 Ferring Pharmaceuticals SWOT Analysis
      • 2.7.4 Ferring Pharmaceuticals Product and Services
      • 2.7.5 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.8 Bristol-Myers Squibb
      • 2.8.1 Bristol-Myers Squibb Details
      • 2.8.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.8.3 Bristol-Myers Squibb SWOT Analysis
      • 2.8.4 Bristol-Myers Squibb Product and Services
      • 2.8.5 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.9 Astellas
      • 2.9.1 Astellas Details
      • 2.9.2 Astellas Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.9.3 Astellas SWOT Analysis
      • 2.9.4 Astellas Product and Services
      • 2.9.5 Astellas Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.10 Dendreon Corporation
      • 2.10.1 Dendreon Corporation Details
      • 2.10.2 Dendreon Corporation Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.10.3 Dendreon Corporation SWOT Analysis
      • 2.10.4 Dendreon Corporation Product and Services
      • 2.10.5 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.11 Sanofi S.A.
      • 2.11.1 Sanofi S.A. Details
      • 2.11.2 Sanofi S.A. Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.11.3 Sanofi S.A. SWOT Analysis
      • 2.11.4 Sanofi S.A. Product and Services
      • 2.11.5 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.12 GlaxoSmithKline plc
      • 2.12.1 GlaxoSmithKline plc Details
      • 2.12.2 GlaxoSmithKline plc Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.12.3 GlaxoSmithKline plc SWOT Analysis
      • 2.12.4 GlaxoSmithKline plc Product and Services
      • 2.12.5 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.13 Roche Healthcare
      • 2.13.1 Roche Healthcare Details
      • 2.13.2 Roche Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.13.3 Roche Healthcare SWOT Analysis
      • 2.13.4 Roche Healthcare Product and Services
      • 2.13.5 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.14 Indevus Pharmaceuticals Inc
      • 2.14.1 Indevus Pharmaceuticals Inc Details
      • 2.14.2 Indevus Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.14.3 Indevus Pharmaceuticals Inc SWOT Analysis
      • 2.14.4 Indevus Pharmaceuticals Inc Product and Services
      • 2.14.5 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
    • 2.15 Ipsen
      • 2.15.1 Ipsen Details
      • 2.15.2 Ipsen Major Business and Total Revenue (Financial Highlights) Analysis
      • 2.15.3 Ipsen SWOT Analysis
      • 2.15.4 Ipsen Product and Services
      • 2.15.5 Ipsen Urological Cancer Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    3 Sales, Revenue and Market Share by Manufacturer

    • 3.1 Global Urological Cancer Therapeutics Drugs Sales and Market Share by Manufacturer (2018-2019)
    • 3.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Manufacturer (2018-2019)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Urological Cancer Therapeutics Drugs Manufacturer Market Share in 2019
      • 3.3.2 Top 6 Urological Cancer Therapeutics Drugs Manufacturer Market Share in 2019
    • 3.4 Market Competition Trend

    4 Global Market Analysis by Regions

    • 4.1 Global Urological Cancer Therapeutics Drugs Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Urological Cancer Therapeutics Drugs Sales and Market Share by Regions (2015-2020)
      • 4.1.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Regions (2015-2020)
    • 4.2 North America Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 4.3 Europe Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 4.4 Asia-Pacific Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 4.5 South America Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 4.6 Middle East and Africa Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)

    5 North America by Country

    • 5.1 North America Urological Cancer Therapeutics Drugs Sales, Revenue and Market Share by Country
      • 5.1.1 North America Urological Cancer Therapeutics Drugs Sales and Market Share by Country (2015-2020)
      • 5.1.2 North America Urological Cancer Therapeutics Drugs Revenue and Market Share by Country (2015-2020)
    • 5.2 United States Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 5.3 Canada Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 5.4 Mexico Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)

    6 Europe by Country

    • 6.1 Europe Urological Cancer Therapeutics Drugs Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Urological Cancer Therapeutics Drugs Sales and Market Share by Country (2015-2020)
      • 6.1.2 Europe Urological Cancer Therapeutics Drugs Revenue and Market Share by Country (2015-2020)
    • 6.2 Germany Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 6.3 UK Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 6.4 France Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 6.5 Russia Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 6.6 Italy Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)

    7 Asia-Pacific by Regions

    • 7.1 Asia-Pacific Urological Cancer Therapeutics Drugs Sales, Revenue and Market Share by Regions
      • 7.1.1 Asia-Pacific Urological Cancer Therapeutics Drugs Sales and Market Share by Regions (2015-2020)
      • 7.1.2 Asia-Pacific Urological Cancer Therapeutics Drugs Revenue and Market Share by Regions (2015-2020)
    • 7.2 China Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 7.3 Japan Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 7.4 Korea Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 7.5 India Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 7.6 Southeast Asia Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 7.7 Australia Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)

    8 South America by Country

    • 8.1 South America Urological Cancer Therapeutics Drugs Sales, Revenue and Market Share by Country
      • 8.1.1 South America Urological Cancer Therapeutics Drugs Sales and Market Share by Country (2015-2020)
      • 8.1.2 South America Urological Cancer Therapeutics Drugs Revenue and Market Share by Country (2015-2020)
    • 8.2 Brazil Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 8.3 Argentina Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)

    9 Middle East & Africa by Countries

    • 9.1 Middle East & Africa Urological Cancer Therapeutics Drugs Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East & Africa Urological Cancer Therapeutics Drugs Sales and Market Share by Country (2015-2020)
      • 9.1.2 Middle East & Africa Urological Cancer Therapeutics Drugs Revenue and Market Share by Country (2015-2020)
    • 9.2 Saudi Arabia Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 9.3 Turkey Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 9.4 Egypt Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)
    • 9.5 South Africa Urological Cancer Therapeutics Drugs Sales and Growth Rate (2015-2020)

    10 Market Segment by Type

    • 10.1 Global Urological Cancer Therapeutics Drugs Sales and Market Share by Type (2015-2020)
    • 10.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Type (2015-2020)
    • 10.3 Global Urological Cancer Therapeutics Drugs Price by Type (2015-2020)

    11 Global Urological Cancer Therapeutics Drugs Market Segment by Application

    • 11.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
    • 11.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
    • 11.3 Global Urological Cancer Therapeutics Drugs Price by Application (2015-2020)

    12 Market Forecast

    • 12.1 Global Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2021-2025)
    • 12.2 Urological Cancer Therapeutics Drugs Market Forecast by Regions (2021-2025)
      • 12.2.1 North America Urological Cancer Therapeutics Drugs Market Forecast (2021-2025)
      • 12.2.2 Europe Urological Cancer Therapeutics Drugs Market Forecast (2021-2025)
      • 12.2.3 Asia-Pacific Urological Cancer Therapeutics Drugs Market Forecast (2021-2025)
      • 12.2.4 South America Urological Cancer Therapeutics Drugs Market Forecast (2021-2025)
      • 12.2.5 Middle East & Africa Urological Cancer Therapeutics Drugs Market Forecast (2021-2025)
    • 12.3 Urological Cancer Therapeutics Drugs Market Forecast by Type (2021-2025)
      • 12.3.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2025)
      • 12.3.2 Global Urological Cancer Therapeutics Drugs Market Share Forecast by Type (2021-2025)
    • 12.4 Urological Cancer Therapeutics Drugs Market Forecast by Application (2021-2025)
      • 12.4.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2025)
      • 12.4.2 Global Urological Cancer Therapeutics Drugs Market Share Forecast by Application (2021-2025)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology
      • 15.2 Data Source
      • 15.3 Disclaimer

      Market Overview
      The global Urological Cancer Therapeutics Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

      The Urological Cancer Therapeutics Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

      Market segmentation
      Urological Cancer Therapeutics Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

      By Type, Urological Cancer Therapeutics Drugs market has been segmented into
      Xofigo (radium Ra 223 dichloride)
      Jevtana (cabazitaxel)
      Inlyta (axitinib)
      Votrient (pazopanib hydrochloride)
      Sutent (sunitinib malate)
      Zytiga (abiraterone acetate)
      Xtandi (enzalutamide)
      Opdivo (nivolumab)
      Provenge (sipuleucel-T)

      By Application, Urological Cancer Therapeutics Drugs has been segmented into:
      Hospital
      Medical Research Laboratory
      Others

      Regions and Countries Level Analysis
      Regional analysis is another highly comprehensive part of the research and analysis study of the global Urological Cancer Therapeutics Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Urological Cancer Therapeutics Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Urological Cancer Therapeutics Drugs market.

      The report offers in-depth assessment of the growth and other aspects of the Urological Cancer Therapeutics Drugs market in important countries (regions), including:
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, etc.)
      Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

      Competitive Landscape and Urological Cancer Therapeutics Drugs Market Share Analysis
      Urological Cancer Therapeutics Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Urological Cancer Therapeutics Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Urological Cancer Therapeutics Drugs sales, revenue and market share for each player covered in this report.

      The major players covered in Urological Cancer Therapeutics Drugs are:
      Novartis
      Celgene Corporation
      AstraZeneca
      Pfizer
      Abbott Laboratories
      Johnson & Johnson
      Ferring Pharmaceuticals
      Bristol-Myers Squibb
      Astellas
      Dendreon Corporation
      Sanofi S.A.
      GlaxoSmithKline plc
      Roche Healthcare
      Indevus Pharmaceuticals Inc
      Ipsen

      Among other players domestic and global, Urological Cancer Therapeutics Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

      The content of the study subjects, includes a total of 15 chapters:
      Chapter 1, to describe Urological Cancer Therapeutics Drugs product scope, market overview, market opportunities, market driving force and market risks.
      Chapter 2, to profile the top manufacturers of Urological Cancer Therapeutics Drugs, with price, sales, revenue and global market share of Urological Cancer Therapeutics Drugs in 2018 and 2019.
      Chapter 3, the Urological Cancer Therapeutics Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
      Chapter 4, the Urological Cancer Therapeutics Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
      Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
      Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
      Chapter 12, Urological Cancer Therapeutics Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
      Chapter 13, 14 and 15, to describe Urological Cancer Therapeutics Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

      Buy now